Spectral AI (MDAI) Q3 2024 earnings summary

Executive summary

• Leadership renewed focus on commercializing AI-driven wound care devices, emphasizing finance, focus, and finish as strategic pillars, with significant support from U.S. government contracts and recent UKCA mark approval for burn indication commercialization in the UK in H2 2024.

• Research & Development revenue increased 138% year-over-year to $8.2 million in Q3 2024, driven by expanded work on U.S. government contracts, especially Project BioShield with BARDA.

• Achieved clinical milestone with last patient out in U.S. Burn Pivotal Study; top line results expected in Q4 2024.

• Announced intent to spin off Spectral IP subsidiary as a new, independent public company, with a $1.0M related party investment.

• In September 2023, completed a business combination and began trading on Nasdaq under the symbols MDAI and MDAIW.

Financial highlights

• Q3 2024 research and development revenue rose 138% year-over-year to $8.2 million, driven by BARDA Project BioShield contract activity.

• Gross margin improved to 44.9% from 42.8% in Q3 2023, reflecting higher reimbursement rates and increased development activity.

• General and administrative expenses declined to $4.6 million (55% of revenue) from $5.6 million (164% of revenue) year-over-year.

• Net loss narrowed to $1.5 million ($0.08/share) from $10.6 million ($0.77/share) in Q3 2023, aided by the absence of prior year’s non-recurring transaction costs.

• Adjusted EBITDA loss was $700,000, a significant improvement from $3.9 million loss in Q3 2023.

Outlook and guidance

• 2024 revenue guidance reiterated at approximately $28 million, a 55% increase over 2023, reflecting BARDA and government contract growth.

• FDA submission for DeepView system targeted for the first half of 2025, with ongoing data collation and algorithm refinement.

• Top-line data from the burn study expected in December 2024, with metrics aligned to FDA requirements.

• Management expects current cash, government contracts, and equity facilities to fund operations for at least one year beyond the financial statement release date, but notes potential need for additional capital if circumstances change.

• Commercialization of DeepView in the UK is expected in the second half of 2024, with ongoing pivotal clinical studies in the U.S.